166 results
6-K
EX-1
BLRX
Bioline Rx Ltd
30 May 24
BioLineRx Announces Clinical Trial Agreement with St. Jude Children’s Research Hospital, Inc. to
7:16am
additional financing, including any unexpected costs or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
any unexpected costs or delays in the ongoing commercialization of APHEXDA;
risks related to changes in healthcare laws, rules and regulations … by payers representing 95% of all covered lives in the U.S. and received a Healthcare Common Procedure Coding System (HCPCS) J-Code to facilitate
6-K
EX-99.1
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies
6-K
EX-99
BLRX
Bioline Rx Ltd
24 May 24
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial
7:05am
related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and BioLineRx's industry
6-K
EX-99
BLRX
Bioline Rx Ltd
17 May 24
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
5:07pm
or delays in the commercial launch of APHEXDA; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere
6-K
EX-99
kl216w2d
6 May 24
Current report (foreign)
7:14am
6-K
EX-99.1
cnbphj1uupvw 6u
17 Apr 24
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4
7:12am
6-K
EX-99
kih f9spbx2pebn3kd
10 Apr 24
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million
7:24am
6-K
EX-99.1
f2nj8v
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
424B5
kuajpp60n
1 Apr 24
Prospectus supplement for primary offering
10:30am
20-F/A
ryf5x6md8bsveowdb hg
26 Mar 24
Annual report (foreign) (amended)
4:57pm
6-K
EX-99
m7oh7oi4p 9a
26 Mar 24
BioLineRx Reports 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
u6wouc98f wy
4 Mar 24
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent
7:47am
6-K
EX-99
ivknzy6w 8rmdh
28 Feb 24
BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial
7:08am
6-K
EX-1
jpx702rmbsiu69z
16 Feb 24
Current report (foreign)
7:07am
F-3
846xdc03 hg
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
siu71a
21 Dec 23
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating
7:05am
6-K
EX-99
xtbzwz 6qs6z
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
ad66mdv
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am